ProCE Banner Activity

First Things First: Why We Need Worldwide Improvement in Screening for HDV

Clinical Thought
To link patients with hepatitis delta virus to care, we first must be able to identify them.

Released: March 08, 2022

Expiration: March 07, 2023

Share

Faculty

Cihan Yurdaydin

Cihan Yurdaydin, MD

Professor and Chief, Department of Gastroenterology and Hepatology
Koç University Medical School
Istanbul, Turkey

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Cihan Yurdaydin, MD

Professor and Chief, Department of Gastroenterology and Hepatology
Koç University Medical School
Istanbul, Turkey

Cihan Yurdaydin, MD, has disclosed that he has received consulting fees from Gilead Sciences and fees for non-CME/CE services from AbbVie and Gilead Sciences.